MEDICAL AFFAIRS

Keep evidence attached from
literature review to field guidance

Ariya turns literature and medical inputs into review-ready drafts with citations, flags, and traceability built in, so evidence survives the journey from review to slide, email, and field.

Book a live walkthrough Tell us your review flow →
Medical evidence connected to strategy and activation diagram

THE CHALLENGE

Medical insights arrive too late,
in the wrong format,
for a decision already made

Evidence gets attached to a deck, summarized once, then disappears into a shared drive.

Commercial, field, and market access make decisions with incomplete visibility into the evidence base.

Medical intelligence lives separately from the decisions it should be informing.

Ariya embeds your evidence directly into the decision workflow — from question to field-ready output.

HOW IT WORKS FOR YOUR TEAM

LITERATURE SYNTHESIS

From PubMed to structured insight

Ariya connects PubMed and internal sources and turns them into structured, searchable evidence. Your team stops hunting across databases and starts getting defensible answers.

EVIDENCE TRACEABILITY

Every claim, traceable to its source

Every output is grounded in your evidence base with full source traceability and audit trail — from publication to field activation. Compliance-ready by design.

MEDICAL-COMMERCIAL ALIGNMENT

One evidence base. Both functions

Both functions work from the same structured evidence layer — so strategy is grounded in science and field messages stay defensible and consistent.

A DAY IN THE LIFE

From literature to field-ready
medical intelligence

01

INPUT

Your evidence base, connected

Clinical study reports, PubMed outputs, congress abstracts, internal medical documents — structured into a single searchable intelligence layer.

02

SYNTHESIZE

Literature synthesis on demand

Ask a clinical or strategic question and Ariya synthesizes across your entire evidence base — surfacing relevant publications, flagging contradictions, and scoring confidence.

03

ALIGN

Medical narrative embedded in strategy

Every commercial output is cross-referenced against your medical evidence layer. Brand strategy, field messages, and market access submissions stay grounded in the same science.

04

ACTIVATE

Field-ready and audit-proof

MSL briefing documents, HCP response guides, and medical affairs memos generated from the same evidence base. Traceable, compliant, and ready to share.

SEE IT IN CONTEXT

What Medical Affairs teams actually ask Ariya

Literature Synthesis

What evidence gaps exist in early identification of Oxymat-eligible patients, and how do they compare to our label?

Ariya
What evidence gaps exist in early identification of Oxymat-eligible patients, and how do they compare to our label?
12 publications indexed.

Key gap: Limited data on early diagnosis and long-term outcomes in paediatric populations.

Recommended action: Prioritize observational study publications and subgroup analyses in upcoming congress submissions.
Confidence: Medium

MSL Briefing

Prepare an MSL briefing on Xypharionyx Pharma's new Phase 3 data and define the appropriate response for Oxymat.

Ariya
Prepare an MSL briefing on Xypharionyx Pharma's new Phase 3 data and define the appropriate response for Oxymat.
MSL briefing generated.

Grounded in: new Phase 3 readout + congress materials + internal CI synthesis.
Key talking points: 4 identified.
Response guidance: within-label comparisons only; no superiority language.
Audit trail: available.

Medical-Commercial Alignment

Does our current Oxymat narrative in Germany align with the latest clinical evidence, and where does it need adjustment?

Ariya
Does our current Oxymat narrative in Germany align with the latest clinical evidence, and where does it need adjustment?
Alignment check complete.
Oxymat narrative consistent with evidence base on 3 of 4 core claims.
Tension identified: efficacy language for the Trialists Segment diverges from current label wording and requires alignment.
Suggested next step: flag for medical review before the next campaign cycle.
"

For the first time, our medical evidence is in the room when commercial decisions are made — not reviewed at the end to check for compliance.

Medical Director, Small biopharmaceutical company focused on rare diseases

★★★★★

Trusted by pharma teams across Europe

Recordati
Galderma
KalVista
Phathom Pharmaceuticals
Arcera

Common questions

Ariya is designed for regulated pharma environments from the ground up. Every output is grounded in your defined evidence base, with full source traceability and audit trail. Your medical and legal review process remains in place — Ariya makes the inputs faster, clearer, and easier to review.

Ariya can connect to PubMed and other literature sources as part of your evidence base. Your medical team defines which sources are in scope, and phamax structures them into the knowledge layer during onboarding. You control what the platform reasons across — no unsanctioned sources are used.

Compliance guardrails are defined during setup and embedded in the platform's reasoning layer. Ariya flags potential compliance issues before outputs are shared and will not generate content outside the boundaries your team defines. Every output includes a compliance flag status and a source trace so your review team can verify quickly and confidently.

Ariya sits upstream of MLR — it structures and drafts content grounded in approved sources, which then goes through your normal review process. The benefit is that inputs to MLR are better organized, fully sourced, and faster to produce. Most teams find MLR cycles shorten because reviewers spend less time chasing source documents.

Both functions access the same shared intelligence layer — but with role-appropriate views and guardrails. Medical Affairs owns the evidence base and sets the compliance boundaries. Commercial Excellence accesses that evidence layer to ground brand strategy and field activation. The result is genuine medical-commercial alignment without requiring a coordination meeting for every output.

Ready to put your evidence
at the center of every decision?

See Ariya in 30 minutes. No slides. A live demo on your context.

Schedule A Demo Talk to the phamax team → See how commercial teams use Ariya →